Circle Pharma Partners with Eli Lilly to Accelerate Next-Generation Cancer Therapies

Strategic Insights -

Circle Pharma, a clinical-stage biopharmaceutical company, has announced an agreement with Eli Lilly and Company to leverage Lilly's AI/ML platform, TuneLab, to enhance its MXMOtm platform in developing macrocycle therapeutics for difficult-to-treat cancers. This collaboration is part of Lilly's Catalyze360 model, which aims to empower early-stage biotechs by providing access to resources and technology. Circle Pharma's lead program, CID-078, a first-in-class cyclin A/B RxL inhibitor, is being evaluated in a Phase 1 clinical trial for patients with advanced solid tumors.

Key Takeaways:

  • Circle Pharma has partnered with Eli Lilly to use Lilly's AI/ML platform, TuneLab, to accelerate the development of next-generation targeted macrocycle therapeutics for cancer.
  • The collaboration will enhance Circle Pharma's MXMOtm platform, enabling it to better predict macrocycle properties and manufacture at scale.
  • Circle Pharma's lead program, CID-078, is a first-in-class, orally bioavailable cyclin A/B RxL inhibitor being evaluated in a Phase 1 clinical trial for patients with advanced solid tumors.
  • The partnership is part of Lilly's comprehensive approach, Catalyze360, to empower early-stage biotechs through access to capital, technology, and resources.
  • Constantine Kreatsoulas, Ph.D., senior vice president at Circle Pharma, highlighted the importance of this collaboration, stating that it will further enhance the company's platform at a time of growth, with multiple programs in development.

Statistics:

  • 100% of Circle Pharma's lead program, CID-078, is being evaluated in a Phase 1 clinical trial for patients with advanced solid tumors.
  • Lilly's Catalyze360 model has been applied to empower early-stage biotechs through access to resources and technologies.
  • The MXMOtm platform has been optimized to better predict the properties of macrocycles and ensure their manufacturability at scale.
  • Lilly's AI/ML platform, TuneLab, has been designed to accelerate the development of new medicines through the provision of AI-trained drug discovery models.

Sources:

  • A news release from Circle Pharma, Inc. (exact text: "Circle Pharma, Inc.")
  • Eli Lilly and Company (Lilly)
  • Constantine Kreatsoulas, Ph.D.
  • Lilly Catalyze360 model documentation and public statements.